Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 610

1.

Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Schädlich PK, Kentsch M, Weber M, Kämmerer W, Brecht JG, Nadipelli V, Huppertz E.

Pharmacoeconomics. 2006;24(6):571-91.

PMID:
16761905
2.

Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.

Schädlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG.

Am J Cardiovasc Drugs. 2007;7(3):199-217.

PMID:
17610347
3.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033
4.
6.

Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.

Shorr AF, Ramage AS.

Crit Care Med. 2001 Sep;29(9):1659-65.

PMID:
11546959
7.

Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.

Deitelzweig SB, Becker R, Lin J, Benner J.

Thromb Haemost. 2008 Nov;100(5):810-20.

PMID:
18989525
8.

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.

Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.

Arch Intern Med. 1999 Jun 14;159(11):1221-8.

PMID:
10371230
9.
10.
11.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
12.

Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.

Offord R, Lloyd AC, Anderson P, Bearne A.

Pharm World Sci. 2004 Aug;26(4):214-20.

PMID:
15446778
13.

Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.

Siddiqui MA, Wagstaff AJ.

Drugs. 2005;65(7):1025-36. Review.

PMID:
15892594
14.
18.

A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.

Lynd LD, Goeree R, Crowther MA, O'Brien BJ.

Can J Clin Pharmacol. 2007 Summer;14(2):e215-26. Epub 2007 Jun 6.

PMID:
17652767
19.

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.

Brosa M, Rubio-Terrés C, Farr I, Nadipelli V, Froufe J.

Pharmacoeconomics. 2002;20(14):979-87.

PMID:
12403638
20.

Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.

Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L.

Pharmacoeconomics. 1999 Nov;16(5 Pt 2):533-42.

PMID:
10662478
Items per page

Supplemental Content

Write to the Help Desk